Circulating Tumor Cell Market Size

Global Circulating Tumor Cell Market Overview

Circulating Tumor Cell Market Size was valued at USD 4.4 billion in 2022 and is projected to grow from USD 4.93 Billion in 2023 to USD 12.29 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.1% during the forecast period (2023 - 2032). The growing demand for companion diagnostics and preventative medication and the increasing incidence of cancer are the key market drivers propelling the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

March 2024 saw the announcement by Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a worldwide leader in life science research and clinical diagnostics products, of the introduction of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated to work with Bio-Rad’s Celselect Slides Enumeration Stain Kits, these are antibodies that specifically recognize CTC surface markers, allowing them to be identified in a sensitive and specific manner, thus providing the chance of understanding the involvement of different populations in terms of tumor heterogeneity and progression at various stages. This product is an easy-to-use customizable benchtop solution that gently and effectively captures many types of CTCs as well as other rare cells from liquid biopsy samples using an unbiased size-based cell selection method.

In February 2024, according to a press release issued by BioXcel Therapeutics, the developer of this therapy, the FDA granted BXCL701 fast-track designation as an investigational oral innate immune activator combined with a checkpoint inhibitor for the treatment of metastatic small cell neuroendocrine prostate cancer (SCNC) patients who have progressed under chemotherapy without microsatellite instability being detected. The combination has already been evaluated for safety and efficacy in phase 2 trials (NCT03910660) involving patients with mCRPC who have either SCNC or adenocarcinoma phenotype. Preliminary findings reported on December 31st, 2023, showed that overall survival was positive for both patient groups when treated with pembrolizumab plus BXCL701.

In April 2024, Naveris, Inc., which pioneers the precision oncology diagnostics for viral-induced cancers, has declared that it is starting off a Phase II clinical trial in MRD+ HPV-driven head and neck cancer. It will be done at Memorial Sloan Kettering Cancer Center (MSKCC), one of the Cancer Treatment and Research Institutes. The main aim of this multicenter randomized study was to assess HB-200 efficacy as a novel intervention among patients with molecular relapse from HPV16+ HNSCC who were defined as having circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA but have not had any recurrence clinically or radiographically after radical therapy. Release of this nature has never been attempted before on this category of patients according to our knowledge.

Circulating Tumor Cell Market Trends

• Growing benefits likes non-invasiveness to boost market growth

Circulating tumor cells are a promising technique in cancer detection because of their non-invasiveness and benefits. The market is also being driven by advances in chip technology, which is another crucial aspect. Circulating tumor cells (CTCs) have been the subject of extensive translational and clinical cancer research initiatives over the past few decades. The development of the market is anticipated to be aided by the ongoing studies being conducted on circulating tumor cell technology by several governmental organizations, including the American Association of Cancer Research and the American Society of Clinical Oncology, to use circulating tumor cells as a surrogate marker for determining the progression of cancer.

The business is anticipated to be driven by the increasing prevalence of various cancer kinds. At 2.26 million cases and 2.21 million cases, breast cancer and lung cancer, respectively, were the most prevalent cancers in 2020. Early cancer identification and adequate cancer treatment and patient care can lessen the disease's burden. The sector is expanding due to the high suitability of circulating cancer cells for creating preclinical models, mainly 3D organoid cultures, for application in drug screening, disease modeling, genome editing, and organoid biobanks.

One of the critical driving demands in this market is the high usage of companion diagnostics in assessing tumor eradication features of cytotoxic medications. The development of CTC-based assays, which may aid in cancer diagnosis, is a continuous focus of key players. Therefore, the such medical condition has recently enhanced the Circulating Tumor Cell market CAGR globally.

Issues with reproducibility and isolation consistency constrain this biomarker's therapeutic relevance. The link between quantification and cancer prognosis implants is another factor driving the growth of the Circulating Tumor Cell market revenue.

Circulating Tumor Cell Market Segment Insights

Circulating Tumor Cell Type Insights

Based on technology, the global Circulating Tumor Cells market segmentation includes research and drug development. The research segment held the majority share in 2022, contributing to around ~65-67% in the Circulating Tumor Cell Market revenue. It is thought that the substrate for cancer metastasis is circulating tumor cells. Enumerating tumor cells in circulation is still primarily a research technique. Recently, the emphasis has switched to characterizing and isolating circulating tumor cells, which can present significant prospects for predictive testing studies

Circulating Tumor Cell Technology Insights

Technology has bifurcated the Circulating Tumor Cell Market data into CTC Enrichment and CTC Detection. The CTC Enrichment segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The circulating lump is either positively or negatively enriched based on biological characteristics. Negative enrichment, however, is the tagging of antigens that are not expressed on CTCs but on other blood plates. Positive enrichment is the capture of tumors. 

Figure 1: Circulating Tumor Cell Market, by Technology, 2022 & 2030 (USD billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

CTC Detection was the fastest-growing segment. Several businesses are investing in creating goods that support downstream assays and CTC analysis. For instance, the CTC analysis products offered by Vortex Biosciences include immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics.

Circulating Tumor Cell End User Insights

Based on End Users, the global Circulating Tumor Cells market segmentation has been segmented into Hospitals & Clinics, Research & Academic Institutes, and Diagnostic Centers. Research & Academic Institutes held the most significant segment share in 2022. This field has substantially advanced cancer research; thus, goods on the market are mainly made for use in lab settings. Parsortix Technology, Target Selector Platform, Apostream, Celsee PREP 400, IsoFlux CTC system, DEPArray System, VTX-1, and AdnaTest are a few notable items that have significantly influenced the vast majority of research settings.

The fastest-growing segment in the Circulating Tumor Cell industry is Diagnostic Centers. The practical efficacy of these cell-based assays has been limited because a significant portion of commercial liquid biopsy tests is based on cell-free DNA (cfDNA). In the market for clinical applications, cfDNA has a smaller market share than circulating tumor cells because it is more commonly used to diagnose cancer.

Circulating Tumor Cell Regional Insights

The report provide markets insights by region, covering North America, Europe, Asia-Pacific, and the rest of the world. The North America circulating tumor cells market had sales of USD 2.01 billion in 2022 and is anticipated to increase at a substantial CAGR over the research period due to increased cancer burden, product approvals, and expanding research and development efforts. For instance, the American Cancer Society, Inc. projects that in 2022, there will be around 236,740 new instances of lung cancer diagnosed in the US. The same source also predicts that 79,000 new instances of kidney cancer and 13,920 kidney cancer-related deaths will be recorded in 2022. The rising prevalence of cancer is anticipated to increase demand for CTC detection kits and propel market expansion.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CIRCULATING TUMOR CELL MARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Circulating Tumor Cells market accounts for the second-largest market share. Also, a vast population susceptible to the disease and a technologically equipped infrastructure for cancer care are some of the key reasons contributing to its enormous share. Further, the Germany Circulating Tumor Cell market held the largest market share, and the UK Circulating Tumor Cell market was the fastest-growing market in the European region.

From 2022 to 2030, the CAGR for the Asia-Pacific Circulating Tumor Cell Market is predicted to be the quickest. This is due to the significant unmet diagnostic needs and the fast-expanding patient awareness of early cancer detection and risk assessment. Moreover, China Circulating Tumor Cell market held the largest market share, and the India Circulating Tumor Cell market was the fastest-growing market in the Asia-Pacific region.

Circulating Tumor Cell Key Market Players & Competitive Insights

Leading market players are spending a lot of money on R&D to increase their product offerings, which will drive further development for the Circulating Tumor Cell market. With significant key development like new product releases, contractual agreements, mergers and acquisitions, higher investments, and cooperation with other organizations, market players are also pursuing various strategy activities to expand their worldwide presence. To develop and survive in an increasingly cutthroat and competitive market climate, Circulating Tumor Cell companies must provide affordable products.

Making locally to reduce running costs is one of the leading marketing strategies manufacturers use in the global Circulating Tumor Cell industry to benefit consumers and expand the industry sector.The circulating tumor cell industry has recently given medicine some of the most important advantages. Major players in the Circulating Tumor Cell market, including Biocept, Inc, Menarini Silicon Biosystem, and others, are attempting to increase market demand by funding R&D initiatives.

For patients whose cancer has spread to their central nervous system, Biocept, Inc. creates and conducts clinical laboratory tests. Their CNSide test offers improved tumor cell detection and analysis from the cerebrospinal fluid and cell-free DNA. In November 2019, The Target SelectorTM pan-TRK assay from Biocept, Inc. a leading commercial provider of liquid biopsy tests intended to give doctors clinically helpful information to enhance the outcomes of patients diagnosed with cancer, is now commercially available. With the Biocept assay, doctors can learn about the probable existence of NTRK fusions and valuable biomarkers that can be used to determine which patients are candidates for therapy with TRK inhibitor medications.

Also, Lab-on-a-chip technologies are created by Silicon Biosystems s.p.a. for specialized cell-biology testing. One of its products is a disposable Lab-on-a-chip called SmartSlide that can perform various tasks on liquid samples, including enrichment, label-free separation, cell mating, and the mating of microbeads. Another product is a cell microarray called DEPArray, which uses technology to manipulate and detect individual cells. Cell sorting and cell-cell interaction applications leverage the company's technology.  In February 2021, A product line called CellMag was introduced by Menarini Silicon Biosystems for the manually enriching and labeling of uncommon circulating tumor cells.

Key Companies in the Circulating Tumor Cell market includes

• STEMCELL Technologies, Inc.


• QIAGEN


• Sysmex Corporation


• Bio-Techne Corporation


• Menarini Silicon Biosystems


• AVIVA Biosciences


• ScreenCell


• Fluxion Biosciences, Inc.


• Creativ MicroTech,


• Biolidics Limited


• IVDiagnostics


• Inc Ikonisys Inc.


• Canopus Bioscience Ltd, among others

Circulating Tumor Cell Industry Developments

July 2021 Datar Cancer Genetics announced the release of a MedTech Innovation Briefing (MIB) from the National Institute for Health and Care Excellence of the United Kingdom on the CE-marked "Trueblood-Prostate" test to be utilized for accurate patient triage and preventative invasive biopsies.

November 2019 A contract was struck by Biolidics Ltd and Sysmex Corporation to create a cancer diagnosis test in a lab.

Circulating Tumor Cell Market Segmentation

Circulating Tumor Cell Type Outlook

• Research


• Drug Development

Circulating Tumor Cell Technology Outlook

• CTC Enrichment


• CTC Detection

Circulating Tumor Cell End User Outlook

• Hospital & Clinics


• Research & Academic Institutes


• Diagnostic Centers

Circulating Tumor Cell Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America